Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESGO 2021 | Results from the JAVELIN Ovarian 200 biomarker analysis

Eric Pujade-Lauraine, MD, PhD, Hôpital Hôtel-Dieu, Paris, France, discusses the results of a biomarker analysis of the JAVELIN Ovarian 200 study (NCT02580058), evaluating avelumab combined with pegylated liposomal doxorubicin in platinum-resistant/refractory ovarian cancer. In this exploratory analysis, biomarkers of response were identified in this patient population. This interview took place at the European Society of Gynaecological Oncology (ESGO) 2021 congress in Prague.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.